Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00098150
First received: December 3, 2004
Last updated: August 29, 2006
Last verified: August 2006
  Purpose

This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.


Condition Phase
Atopic Dermatitis
Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by Novartis:

Estimated Enrollment: 66
Study Start Date: July 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consenting patients who participated in the core clinical trial
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00098150     History of Changes
Other Study ID Numbers: Ext 1 to ASM981C202
Study First Received: December 3, 2004
Last Updated: August 29, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Safety, atopic dermatitis, adverse event, SAE, extension

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Pimecrolimus
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 16, 2014